Vertex Pharmaceuticals
VRTX • NASDAQ
Vertex Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Reshma Kewalramani, with a market cap of $121.15B.
CEOReshma Kewalramani
Market Cap$121.15B
Biotechnology
Healthcare
Employees5.4K
Websitevrtx.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Vertex Pharmaceuticals
Date
Monday, May 4, 2026 (in 2 months)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
$4.21
Revenue Estimate
$3.1B
Earnings History
Past 12 earnings reports for Vertex Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 12, 2026 | Q4 2025 | $5.03Est: $4.85 | +3.7% | $3.2BEst: $3.2B | +0.5% |  10-K |
| Nov 3, 2025 | Q3 2025 | $4.80Est: $4.35 | +10.3% | $3.1BEst: $3.1B | +0.8% | 10-Q |
| Aug 4, 2025 | Q2 2025 | $4.52Est: $4.05 | +11.6% | $3.0BEst: $2.9B | +2.2% | 10-Q |
| May 5, 2025 | Q1 2025 | $4.06Est: $4.29 | -5.4% | $2.8BEst: $2.9B | -3.1% | 10-Q |
| Feb 10, 2025 | Q4 2024 | $3.98Est: $4.02 | -1.0% | $2.9BEst: $2.8B | +4.7% | 10-K |
| Nov 4, 2024 | Q3 2024 | $4.38Est: $4.14 | +5.8% | $2.8BEst: $2.7B | +1.9% | 10-Q |
| Aug 1, 2024 | Q2 2024 | -$12.83Est: $4.14 | -409.9% | $2.6BEst: $2.7B | -0.5% | 10-Q |
| May 6, 2024 | Q1 2024 | $4.76Est: $4.02 | +18.4% | $2.7BEst: $2.6B | +4.7% | 10-Q |
| Feb 5, 2024 | Q4 2023 | $4.20Est: $4.10 | +2.4% | $2.5BEst: $2.5B | +0.3% | 10-K |
| Nov 6, 2023 | Q3 2023 | $4.08Est: $3.98 | +2.5% | $2.5BEst: $2.5B | -0.6% | — |
| Aug 1, 2023 | Q2 2023 | $3.89Est: $3.85 | +1.0% | $2.5BEst: $2.4B | +3.4% | 10-Q |
| May 1, 2023 | Q1 2023 | $3.05Est: $3.00 | +1.7% | $2.4BEst: $2.3B | +1.5% | — |